Corstasis Announces FDA Acceptance for Bumetanide Nasal Spray
PDUFA Target Action Date Set for September 14, 2025 Corstasis Therapeutics Inc. (www.corstasis.com), a clinical-stage MedTech pharmaceutical company developing innovative, practical therapies for fluid overload,...